AU2018204285A1 - Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders - Google Patents

Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders

Info

Publication number
AU2018204285A1
AU2018204285A1 AU2018204285A AU2018204285A AU2018204285A1 AU 2018204285 A1 AU2018204285 A1 AU 2018204285A1 AU 2018204285 A AU2018204285 A AU 2018204285A AU 2018204285 A AU2018204285 A AU 2018204285A AU 2018204285 A1 AU2018204285 A1 AU 2018204285A1
Authority
AU
Australia
Prior art keywords
masp
disorders
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2018204285A
Other versions
AU2018204285B2 (en
Inventor
Gregory A. Demopulos
Thomas Dudler
Patrick Gray
Hans-Wilhelm Schwaeble
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leicester
Omeros Corp
Original Assignee
University of Leicester
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013277309A external-priority patent/AU2013277309B2/en
Application filed by University of Leicester, Omeros Medical Systems Inc filed Critical University of Leicester
Priority to AU2018204285A priority Critical patent/AU2018204285B2/en
Publication of AU2018204285A1 publication Critical patent/AU2018204285A1/en
Application granted granted Critical
Publication of AU2018204285B2 publication Critical patent/AU2018204285B2/en
Priority to AU2020202999A priority patent/AU2020202999B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

AU2018204285A 2012-06-18 2018-06-15 Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders Active AU2018204285B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018204285A AU2018204285B2 (en) 2012-06-18 2018-06-15 Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders
AU2020202999A AU2020202999B2 (en) 2012-06-18 2020-05-06 Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261661167P 2012-06-18 2012-06-18
US61/661,167 2012-06-18
AU2013277309A AU2013277309B2 (en) 2012-06-18 2013-06-18 Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders
PCT/US2013/046432 WO2013192240A2 (en) 2012-06-18 2013-06-18 Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
AU2018204285A AU2018204285B2 (en) 2012-06-18 2018-06-15 Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2013277309A Division AU2013277309B2 (en) 2012-06-18 2013-06-18 Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020202999A Division AU2020202999B2 (en) 2012-06-18 2020-05-06 Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders

Publications (2)

Publication Number Publication Date
AU2018204285A1 true AU2018204285A1 (en) 2018-07-05
AU2018204285B2 AU2018204285B2 (en) 2020-02-27

Family

ID=49769678

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013277309A Active AU2013277309B2 (en) 2012-06-18 2013-06-18 Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders
AU2018204285A Active AU2018204285B2 (en) 2012-06-18 2018-06-15 Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders
AU2020202999A Active AU2020202999B2 (en) 2012-06-18 2020-05-06 Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2013277309A Active AU2013277309B2 (en) 2012-06-18 2013-06-18 Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020202999A Active AU2020202999B2 (en) 2012-06-18 2020-05-06 Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders

Country Status (27)

Country Link
US (3) US20130344073A1 (en)
EP (4) EP3058951A1 (en)
JP (4) JP6445972B2 (en)
KR (4) KR102339315B1 (en)
CN (3) CN109908352A (en)
AU (3) AU2013277309B2 (en)
BR (1) BR112014031522A2 (en)
CA (2) CA2875567C (en)
CL (2) CL2014003455A1 (en)
CY (1) CY1124234T1 (en)
DK (1) DK2861246T3 (en)
ES (1) ES2864857T3 (en)
HK (1) HK1209623A1 (en)
HR (1) HRP20210559T1 (en)
HU (1) HUE053727T2 (en)
IL (2) IL236327B (en)
IN (1) IN2015KN00015A (en)
LT (1) LT2861246T (en)
MX (3) MX2014015715A (en)
NZ (1) NZ629473A (en)
PL (1) PL2861246T3 (en)
PT (1) PT2861246T (en)
RS (1) RS61755B1 (en)
RU (2) RU2019140356A (en)
SI (1) SI2861246T1 (en)
WO (1) WO2013192240A2 (en)
ZA (1) ZA201500094B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
PL3287142T3 (en) 2011-04-08 2021-12-27 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
US9217042B2 (en) * 2012-10-23 2015-12-22 Abbott Cardiovascular Systems Inc. Method of reducing MACE in diabetic patients subsequent to stent placement
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
NZ729747A (en) 2013-03-15 2020-03-27 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
KR20210130260A (en) 2013-04-02 2021-10-29 추가이 세이야쿠 가부시키가이샤 Fc region variant
EP2983710B1 (en) * 2013-04-09 2019-07-31 Annexon, Inc. Methods of treatment for neuromyelitis optica
ES2753419T3 (en) * 2013-06-07 2020-04-08 Univ Duke Complement factor H inhibitors
NZ715455A (en) 2013-07-09 2021-12-24 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
EP3057993B1 (en) 2013-10-17 2020-08-12 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
EP3151845A4 (en) * 2014-06-05 2018-01-17 The Regents of the University of Colorado, a body corporate Map44 polypeptides and constructs based on natural antibodies and uses thereof
BR112017009297B1 (en) 2014-11-05 2024-02-15 Annexon, Inc HUMANIZED C1Q COMPLEMENT ANTIFATOR ANTIBODIES, PHARMACEUTICAL COMPOSITION AND KIT COMPRISING THE SAME, THERAPEUTIC USE THEREOF, ISOLATED POLYNUCLEOTIDE, ISOLATED HOST CELL, AS WELL AS IN VITRO METHODS FOR DETECTING SYNAPSES
US10639307B2 (en) 2015-05-15 2020-05-05 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of preeclampsia comprising administration of ADAMTS13 polypeptides
CA2987976A1 (en) * 2015-06-03 2016-12-08 Coyne Ip Holdings, Llc Methods for establishing threshold limits for a chemical or biological agent in a target species
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (en) * 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
KR102432062B1 (en) * 2015-11-09 2022-08-12 오메로스 코포레이션 Methods for treating conditions associated with masp-2 dependent complement activation
CN115260310A (en) 2015-11-24 2022-11-01 安尼艾克松股份有限公司 FAB fragment of anti-complement factor C1Q and application thereof
US10736960B2 (en) * 2016-01-05 2020-08-11 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
IL305200A (en) 2016-03-31 2023-10-01 Omeros Corp Masp-2 inhibitory agents for use in inhibiting angiogenesis
JOP20170154B1 (en) 2016-08-01 2023-03-28 Omeros Corp Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
JOP20170170B1 (en) 2016-08-31 2022-09-15 Omeros Corp Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018186322A1 (en) * 2017-04-03 2018-10-11 Chugai Seiyaku Kabushiki Kaisha Anti-masp-1 antibodies and methods of use
AU2018322032A1 (en) * 2017-08-25 2020-03-12 Omeros Corporation Highly concentrated low viscosity MASP-2 inhibitory antibody formulations, kits, and methods of treating subjects suffering from atypical hemolytic syndrome
BR112020018357A2 (en) * 2018-04-13 2020-12-29 Chugai Seiyaku Kabushiki Kaisha ANTICOMPLEMENT COMPONENT ANTIBODIES AND METHODS OF USE
EP3836965A4 (en) * 2018-06-22 2022-04-20 Omeros Corporation Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders
KR20210057086A (en) 2018-09-06 2021-05-20 아칠리온 파르마세우티칼스 인코포레이티드 The morphological form of Danicopan
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
BR112021005506A2 (en) 2018-09-25 2021-06-15 Achillion Pharmaceuticals, Inc. morphic forms of complementary factor inhibitors d
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
EP3966226A1 (en) 2019-05-07 2022-03-16 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
US20210171461A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
JP2023504543A (en) 2019-12-04 2023-02-03 オメロス コーポレーション MASP-2 inhibitors and methods of use
IL293588A (en) 2019-12-04 2022-08-01 Omeros Corp Masp-2 inhibitor compounds, compositions comprising same and uses thereof
CN115052862A (en) 2019-12-04 2022-09-13 奥默罗斯公司 MASP-2 inhibitors and methods of use
CN112237630A (en) * 2020-02-21 2021-01-19 中国人民解放军军事科学院军事医学研究院 Application of substance aiming at MASP-2, coronavirus N protein or combination thereof in preparation of drugs for diseases caused by coronaviruses
TW202319069A (en) * 2020-03-06 2023-05-16 美商奥默羅斯公司 Methods of inhibiting masp-2 for the treatment and/or prevention of acute respiratory distress syndrome, pneumonia or some other pulmonary manifestation of influenza virus infection induced by influenza virus
CN115215937B (en) 2021-04-15 2023-05-26 上海麦济生物技术有限公司 Anti-human MASP-2 antibody, preparation method and application thereof
CN114989259B (en) * 2022-05-27 2023-06-09 成都佩德生物医药有限公司 Small molecule peptide Ped4 and application thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
JP3218637B2 (en) 1990-07-26 2001-10-15 大正製薬株式会社 Stable aqueous liposome suspension
JP2958076B2 (en) 1990-08-27 1999-10-06 株式会社ビタミン研究所 Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
CA2391402A1 (en) * 1999-12-02 2001-06-07 Jens Christian Jensenius Masp-3, a complement-fixing enzyme, and uses for it
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
PT1344533E (en) * 2002-03-15 2007-01-31 Natimmune As Pharmaceutical compositions comprising mannose binding lectin
ES2601143T3 (en) 2002-07-19 2017-02-14 Omeros Corporation Biodegradable triblock copolymers, synthesis methods thereof, and hydrogels and biomaterials prepared therefrom.
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
AU2004216176B2 (en) * 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
WO2005005630A2 (en) * 2003-07-08 2005-01-20 Umc Utrecht Holding B.V. Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases
EP3530288A3 (en) * 2004-06-10 2019-12-18 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN100518905C (en) * 2004-11-02 2009-07-29 浙江欧美环境工程有限公司 Turning type electric desalinization device
WO2007024715A2 (en) 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2626356C (en) * 2005-10-21 2017-08-22 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
RU2477137C2 (en) * 2006-03-08 2013-03-10 АРКЕМИКС Эл Эл Си Complement-binding aptamers and c5 agents applicable for treating ocular disorders
CA2685714C (en) 2007-05-31 2016-04-12 University Of Washington Inducible mutagenesis of target genes
CA2742802C (en) * 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20110002931A1 (en) * 2009-06-23 2011-01-06 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
AU2010272483B2 (en) * 2009-07-17 2016-07-21 Omeros Corporation MASP isoforms as inhibitors of complement activation
PT2488203T (en) * 2009-10-16 2017-03-10 Univ Leicester Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
CA2791841C (en) * 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
US8795973B2 (en) * 2010-11-29 2014-08-05 University of Leceister Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof
PL3287142T3 (en) * 2011-04-08 2021-12-27 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
SI2833907T1 (en) * 2012-04-06 2018-07-31 Omeros Corporation Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria

Similar Documents

Publication Publication Date Title
AU2018204285A1 (en) Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders
HK1209623A1 (en) Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders masp-1 / masp-2 / masp-3
EP3177732A4 (en) Compositions and methods for the treatment of ophthalmic diseases and conditions
HUE041553T2 (en) Methods and compositions for the treatment of monogenic diseases
EP3490603A4 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
IL241264A0 (en) Compounds and compositions for the treatment of parasitic diseases
EP3137116A4 (en) Dendrimer compositions and their use in treatment of diseases of the eye
IL239368A0 (en) Ppar-sparing thiazolidiones and combinations for the treatment of neurodegenerative diseases
LT2925757T (en) Compounds and compositions for the treatment of parasitic diseases
HK1198909A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
EP3268007A4 (en) Compositions and therapeutic methods for the treatment of complement-associated diseases
EP3086809A4 (en) Compositions and methods of treating ocular diseases
EP3481958A4 (en) Methods and compositions for treatment of disorders and diseases involving rdh12
EP3043817A4 (en) Methods and compositions for treatment of chlamydial infection and related diseases and disorders
EP3393460A4 (en) Compositions and methods of treatment for mvid and related diseases
HK1216721A1 (en) Uses and methods for the treatment of liver diseases or conditions
EP3107534A4 (en) Compositions and methods for the treatment of neurodegenerative diseases
EP3119387A4 (en) Compositions for the treatment of dermatological diseases and disorders
EP3402511A4 (en) Compositions and methods for treatment of ocular diseases
EP3362085A4 (en) Compositions and methods for the treatment of diseases involving mucin
EP3065548A4 (en) Fibrosis inhibiting compounds and methods of use thereof in the prevention or treatment of fibrosing diseases
EP3247396A4 (en) Methods and compositions for the treatment of diseases and disorders
AU2016901682A0 (en) Compositions for the Treatment of Diseases and Conditions
EP3129054A4 (en) Methods and compositions for the treatment of ocular diseases and disorders
EP3328428A4 (en) Methods and compositions for the treatment of immunomodulatory diseases and disorders